Literature DB >> 20397063

Erythropoietin-responsive sites in normal and malignant human lung tissues.

Yoshiko Yasuda1, Satoshi Hara, Takeshi Hirohata, Eiji Koike, Harufumi Yamasaki, Katsumi Okumoto, Hiroshi Hoshiai.   

Abstract

Preliminary findings of various types of globin expressed in the respiratory bronchiolar and alveolar epithelium prompted us to compare the expression of erythropoietin (Epo) and its receptor (EpoR) in normal (healthy) human lung tissues with that in malignant lung tissues. The expression of Epo and EpoR was examined at the transcriptional and protein levels in normal and malignant lung tissues by reverse transcription-PCR, western blot, and immunohistochemical analyses. EpoR mRNA, but not Epo mRNA, was detected in all samples. In normal tissues, EpoR was detected in the mesothelium, chondrocytes, alveolar cells, vascular endothelial cells, smooth muscle fibers, macrophages, and neutrophils, while in malignant foci, the cancer cells of five malignant types showed various intensities of EpoR immunoreactivity. The pattern of staining of EpoR protein was generally stronger in the malignant tissues than in the normal samples. Phosphorylation of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK-ERK1/2) was frequently seen in malignant cells, but not in the normal tissues, with the exception of macrophages. Based on the expression of Epo and EpoR mRNA with the EpoR in almost all cell components in normal tissues, we suggest that the normal lung may produce various types of globin through the autocrine and/or paracrine role of Epo. When the Epo signal is upregulated by hypoxic stress, the normal cells appear to transform into malignant cells and proliferate through activated MAPK signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20397063     DOI: 10.1007/s12565-010-0081-7

Source DB:  PubMed          Journal:  Anat Sci Int        ISSN: 1447-073X            Impact factor:   1.741


  7 in total

1.  Erythropoietin upregulation in pulmonary arterial hypertension.

Authors:  Vanesa A Karamanian; Michael Harhay; Gregory R Grant; Harold I Palevsky; William E Grizzle; Roham T Zamanian; Kaori Ihida-Stansbury; Darren B Taichman; Steven M Kawut; Peter L Jones
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

2.  Erythropoietin Receptor Antagonist Suppressed Ectopic Hemoglobin Synthesis in Xenografts of HeLa Cells to Promote Their Destruction.

Authors:  Yoshiko Yasuda; Mitsugu Fujita; Eiji Koike; Koshiro Obata; Mitsuru Shiota; Yasushi Kotani; Terunaga Musha; Sachiyo Tsuji-Kawahara; Takao Satou; Seiji Masuda; Junko Okano; Harufumi Yamasaki; Katsumi Okumoto; Tadao Uesugi; Shinichi Nakao; Hiroshi Hoshiai; Masaki Mandai
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

3.  Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma.

Authors:  Anita Rózsás; Judit Berta; Lívia Rojkó; László Z Horváth; Magdolna Keszthelyi; István Kenessey; Viktória László; Walter Berger; Michael Grusch; Mir Alireza Hoda; Szilvia Török; Walter Klepetko; Ferenc Rényi-Vámos; Balázs Hegedűs; Balázs Döme; József Tóvári
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

4.  Association of erythropoietin gene rs576236 polymorphism and risk of adrenal tumors in a Chinese population.

Authors:  Chao Zhang; Zhongxing Li; Qiang Cao; Chao Qin; Hongzhou Cai; Hai Zhou; Jian Qian; Liangjun Tao; Xiaobing Ju; Changjun Yin
Journal:  J Biomed Res       Date:  2014-08-11

5.  TAM-ing the CIA-Tumor-Associated Macrophages and Their Potential Role in Unintended Side Effects of Therapeutics for Cancer-Induced Anemia.

Authors:  Stefan Weiler; Manfred Nairz
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

6.  Ventilatory and Autonomic Regulation in Sleep Apnea Syndrome: A Potential Protective Role for Erythropoietin?

Authors:  David C Andrade; Liasmine Haine; Camilo Toledo; Hugo S Diaz; Rodrigo A Quintanilla; Noah J Marcus; Rodrigo Iturriaga; Jean-Paul Richalet; Nicolas Voituron; Rodrigo Del Rio
Journal:  Front Physiol       Date:  2018-10-16       Impact factor: 4.566

7.  Suppression of NLRP3 Inflammasome by Erythropoietin via the EPOR/JAK2/STAT3 Pathway Contributes to Attenuation of Acute Lung Injury in Mice.

Authors:  Fei Cao; Xinyi Tian; Zhongwang Li; Ya Lv; Jun Han; Rong Zhuang; Bihuan Cheng; Yuqiang Gong; Binyu Ying; Shengwei Jin; Ye Gao
Journal:  Front Pharmacol       Date:  2020-03-19       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.